Dementia is increasing in Australia in line with population ageing and is expected to peak by mid-century. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
39/100
Insomnia is associated with socioeconomic status, racial and ethnic classification, family relationships, medical and mental health disorders, cognitive function, and dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep problems occur commonly in normal and pathologic aging. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Insomnia is a common sleep disorder among older adults, and a risk factor for poor physical and mental health. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep and wakefulness disorders are commonly seen in patients with Parkinson's disease, Lewy body dementia and Alzheimer's disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Decreased sleep time in the elderly is a precipitating factor in amyloid retention. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obstructive sleep apnea (OSA) is a prevalent sleep related breathing disorder characterized by repetitive collapse of the upper airways leading to intermittent hypoxia and sleep disruption. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
In the world, the spread of hearing loss due to age is an important socio-medical problem. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Many studies have focused on the relationship between hearing loss and Alzheimer's Disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In addition to the well-documented relationship between peripheral hearing loss and cognition highlighted in previous comprehensive reviews, there is also some evidence to suggest that there is a relationship between central hearing impairment and cognition. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
Studies have linked obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Until recently, intraindividual visit-to-visit variability of cardiovascular risk factors has been dismissed as random fluctuation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
Neurodegenerative disorders are the most devastating disorder of the nervous system. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Similar to other complex disorders, the etiology of Alzheimer disease is multifactorial and characterized by an interplay of biological and environmental risk and protective factors. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research into cognitive reserve (CR) and dementia is advancing rapidly. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Despite the large number of elderly bilinguals at risk for Alzheimer's disease (AD) and dementia worldwide, significant questions remain about the relationship between speaking more than one language and later cognitive decline. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We examined associations between cognitive reserve and late-life amyloid-β deposition using florbetapir positron emission tomography (PET). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
Brain age prediction is a machine learning method that estimates an individual's chronological age from their neuroimaging scans. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Three major neurobiological features shared by LLD and AD include neurodegeneration, disruption to cerebrovascular functioning, and increased levels of neuroinflammation. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article covers current research on the relationship between depression and cognitive impairment in older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older adults with depression showed increased ReHo in the bilateral dorsal anterior cingulate cortex (dACC) and the right middle temporal gyrus, with no significant findings for network homogeneity. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although cognitive and functional impairment are the hallmark features of Alzheimer's disease (AD), neuropsychiatric symptoms associated with AD account for increased rates of disability and profoundly impact the quality of life of both patients and their caregivers. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia has become a major public health concern around the world. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Among cognitively normal individuals, a 5 μg/m3 increase in 7-day and 1-year average PM2.5 was associated with elevated VCAM-1 (7-day: 35.4 (9.7, 61.1) ng/ml; 1-year: 51.8 (6.5, 97.1) ng/ml). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
In these models, PM2.5 concentration was associated with smaller left hippocampal volume. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →